FDA grants QIDP Designation For Kinnear's CSA-131 drug for Life-threatening Pseudomonas Bacterial Infections in CF
FDA QiDP designation is a signifcant milestone PARK CITY, UTAH, UNITED STATES, July 31, 2023 /EINPresswire.com/ -- Kinnear Pharmaceuticals, LLC, a subsidiary of N8 Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted …